Apyx Medical heads into its third-quarter report with a peculiar disconnect. The operating story management told in August was still improving, with double-digit growth, rising gross margins and the long-delayed FDA clearance for power liposuction finally in hand. Yet the stock has lost roughly 40% since then, while the S&P 500 was essentially flat. The November 5 release, due before the open, is the first full quarter of the power liposuction rollout. That makes it the first real evidence of whether the catalyst investors waited years for is translating into sales, or whether the market's skepticism has been justified.

The Street is not asking for much on the top line. Consensus calls for revenue of $13.6 million, up about 6% from a year ago but slightly below the $13.9 million Apyx posted last quarter. That is a sharp slowdown from the 22% growth reported in the second quarter and the 32% pace in the first. Part of the deceleration is deliberate. Management now expects the OEM business to shrink to about $5 million this year from $7.5 million in 2025 as resources shift toward aesthetics. With roughly $3.3 million of OEM revenue already booked in the first half, the second half implies a steep drop in that line. The more telling figure is surgical aesthetics, which grew 28% last quarter. If that segment keeps compounding at a healthy clip while OEM fades, the headline slowdown matters far less. On the bottom line, analysts expect a loss of $0.07 per share, matching the prior quarter but wider than the $0.05 loss a year earlier.

Full-year guidance frames the stakes. Apyx raised its 2026 revenue outlook to $59 million to $60 million in the first quarter, then merely reaffirmed it in August. Consensus of $59.52 million sits squarely at the midpoint. Combine the first-half results with the third-quarter estimate and the Street is effectively counting on a fourth quarter of roughly $19.5 million, about level with last year's record $19.2 million. The shift from raising to reaffirming is a reasonable signal that management sees momentum holding rather than accelerating. A third raise would therefore be a genuine surprise, while any trim would land hard on a stock already under pressure.

The operational questions follow directly from the last call. Management said full launch of power liposuction was planned for the third quarter and expected more than 95% of new Aon systems to ship with the reusable handpieces. Evidence of that attach rate, along with continued sales of Aon to buyers outside the existing Renuvion base, would validate the thesis that the platform is broadening and adding recurring revenue. Gross margin is the second swing factor. It reached 63.9% last quarter, above the 62% to 63% full-year range, but management warned that tariffs and elevated handpiece costs during the ramp would cause some give-back in the second half. A modest dip is already baked in. A slide below the guided range would not be. Cash also matters: operating burn jumped to $3.5 million in the second quarter on working capital swings, and cash fell to $27.6 million. A return toward the lighter burn of the first quarter would ease runway concerns.

Sentiment has turned more bullish than it was ahead of the August report, even as the shares sank. At $2.50, the stock trades well below its 200-day moving average of $3.62 and sits near the bottom of its post-earnings range of $2.25 to $4.25, a range that has shifted noticeably lower than the prior quarter's. That leaves room for relief if the numbers hold up, but little cushion if they do not.

Ultimately, this report hinges on whether power liposuction is visibly lifting Aon demand and handpiece revenue fast enough to support a fourth-quarter record without breaking margins or draining cash. If it is, the selloff looks overdone. If it is not, reaffirmed guidance may start to look like a ceiling.